Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. Blood Adv 2022 Apr 26;6(8):2466-2470
Date
12/22/2021Pubmed ID
34933344Pubmed Central ID
PMC9043928DOI
10.1182/bloodadvances.2021006178Scopus ID
2-s2.0-85129331026 (requires institutional sign-in at Scopus site) 25 CitationsAuthor List
Mohan M, Nagavally S, Dhakal B, Radhakrishnan SV, Chhabra S, D'Souza A, Hari PAuthors
Anita D'Souza MD Associate Professor in the Medicine department at Medical College of WisconsinBinod Dhakal MD Associate Professor in the Medicine department at Medical College of Wisconsin
Sabarinath Venniyil Radhakrishnan MD Assistant Professor in the Medicine department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
B-Cell Maturation AntigenHumans
Immunologic Factors
Immunotherapy
Multiple Myeloma
